'Very real' headwinds: With leaner staff, cancer vaccine maker searches for help
Cancer vaccine biotech IMV said it will look at “strategic alternatives following a review of its business” as the Canadian company continues clinical trials.
The Nova Scotia and Cambridge, MA biotech laid off about one-third of its staff last fall to “maximize shareholder value.” Now, IMV wants to “realize its full clinical potential” in solid and hematologic cancers and has tapped Stonegate Healthcare Partners to figure that out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.